CorEuStem 2025: Pioneering the Future of Stem Cell Collaboration in Europe

CorEuStem 2025: Pioneering the Future of Stem Cell Collaboration in Europe

CorEuStem COST Action CA20140 would like to call the attention to all members, Core Facilities and R&D partners to save the date on CorEuStem 2025: Pioneering the Future of Stem Cell Core Facilities in Europe that will take place on May 29-30th, 2025 at Human Technopole (HT) in Milan, Italy.

The European Network for Stem Cell Core Facilities will be hosting CorEuStem 2025 to unite scientists from stem cell core facilities across Europe. The event aims to discuss the latest advances in stem cell biology, disease modelling, and genome editing, pioneered by these facilities. A key focus will be on standardising and harmonising protocols across Europe, as well as exploring new technologies to enhance collaboration and efficiency in the field.

We foresee the attendance of circa 120 participants and the event will consist of on-site lectures, two poster sessions, and a final session dedicated to the achievements of the working groups composing our network.

CorEuStem 2025 is organised by Giovanni Fagà and Jacopo Zasso, Genome Engineering and Disease Modelling Facility at HT (Italy), Laura Batlle Morera, Tissue Engineering Unit at CRG (Spain), Laurent David, iPSC Core Facility at Université de Nantes (France), Inês Figueira, NOVA Medical School in Lisbon (Portugal), Adrien Roux, HEPIA in Geneva (Switzerland), Katriina Aalto-Setälä, Tampere University (Finland).

More detailed information will be provided shortly. For the moment, information on how to support the event can be found at: CorEuStem 2025: Pioneering the Future of Stem Cell Collaboration in Europe – Human Technopole

Facebook
Twitter
LinkedIn
WhatsApp
Email

news

Latest Updates

We are excited to announce an upcoming hands-on training workshop on the 2D and 3D Differentiation of Human Pluripotent Stem Cells (hPSCs). This workshop is designed to provide in-depth knowledge and practical experience in cutting-edge differentiation protocols. Workshop Highlights: Who Should Attend: This workshop is ideal for: PhD Students, Postdocs, Early Career Researchers, Principal Investigators,...

The Core Group of CorEuStem COST Action gathered in Hamburg, Germany, at the Zentrum für Molekulare Neurobiologie Hamburg (ZMNH) on the 8th and 9th of July 2024. Hosted by the WG6 leader, Ole Pless, the meeting covered important topics and discussions on the different WGs objectives and upcoming deliverables, as well as a focus session...

The CorEuStem Training School 2024 – Advances in reprogramming & CRISPR/Cas9 took place at the Centre for Genomic Regulation (CRG) in Barcelona, Spain, on 16th April 2024. The meeting gathered experts from the different core facilities in Europe, covering the latest advances in human stem cells and gene editing technologies. Invited speakers included: Dr Ana Belén Álvarez-Palomo (Banc de Sang i Teixits, Barcelona,...

CorEuStem is proud to announce the official launch of the European Core Facilities Database on our webpage! Please take a look at it here. CorEuStem COST Action led the initiative to compile all Stem Cell and Gene Editing Core Facilities running in Europe, as well as the main services provided by each one of them...

European University Initiative (EUTOPIA) week took place from 4 to 6 December 2023 at the Technische Universität Dresden (TUD), Dresden, Germany. Among the different aspects covered, during the EUTOPIA Research Infrastructures Cooperation Symposium, Interinstitutional/European Research Infrastrutures Networks were presented and discussed, including an hybrid talk given by CorEuStem members, Dr. Inês Figueira (NOVA University Lisbon) and...

Next CorEuStem webinar will be held November 9th, 2023, 11.00 – 12:00 (CET). Please register here to attend. Speaker: Dr. Leszek LisowskiChildren’s Medical Research Institute (CMRI)The University of Sydney, Australia Dr. Leszek Lisowski is a world vectorology expert with over 15 years of experience in developing and manufacturing viral vectors for human gene therapy. Currently,...